Evidence map›Paper›PMID 27922077›Full record

ArticleScientific reports2016

Mast cell phenotype, TNFα expression and degranulation status in non-small cell lung cancer.

A Shikotra, C M Ohri, R H Green, D A Waller, P Bradding

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 48 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Prognostic value ofHeliyon · 2023
    Article
  7. Review
  8. Article
  9. Article
  10. Human Lung Mast Cells: Therapeutic Implications in Asthma.International journal of molecular sciences · 2022
    Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Role of Mast Cells in Shaping the Tumor Microenvironment.Clinical reviews in allergy & immunology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

A ShikotraInstitute for Lung Health, Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK.
C M OhriUniversity Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester, UK.
R H GreenUniversity Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester, UK.
D A WallerUniversity Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester, UK.
P BraddingInstitute for Lung Health, Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK.
University Hospitals of Leicester NHS Trust · GBUniversity of Leicester · GBGlenfield Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mast cell infiltration of tumour islets represents a survival advantage in non-small cell lung cancer (NSCLC). The phenotype and activation status of these mast cells is unknown. We investigated the mast cell phenotype in terms of protease content (tryptase-only [MC

Indexed as

AgedCarcinoma, Non-Small-Cell LungCell DegranulationCell MovementChymasesCytotoxicity, ImmunologicFemaleGene ExpressionHumansLung NeoplasmsMaleMast CellsMiddle AgedPhenotypeSurvival AnalysisTryptasesChymasesTryptasesTumor Necrosis Factor-alpha

Identifiers

PMID27922077
PMCPMC5138591
OpenAlexW2560410777

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.